ポイントオブケア診断の世界市場：洞察、競合情勢、市場予測：2030年

世界のポイントオブケア診断の市場規模は、2024年から2030年までの予測期間中に6.61%のCAGRで拡大すると予測されています。ポイントオブケア診断薬に対する需要は、主に糖尿病や心血管疾患などの様々な生活習慣病に罹患する患者人口の増加、感染症の有病率の上昇、健康と無病息災に対する意識の高まり、製品開発における技術革新などによって後押しされており、2024年から2030年までの予測期間においてポイントオブケア診断薬市場全体の成長に寄与しています。

世界保健機関（WHO）の2022年のデータによると、世界全体で約3億5,400万人が肝炎と闘っています。また、WHOの推定に基づく疾病対策予防センター（CDC）2022によると、2019年には世界で約2億9,600万人がB型肝炎に罹患し、5,800万人がC型肝炎とともに生活し、150万人がB型慢性肝炎に新たに感染し、150万人のC型慢性肝炎の新規症例が報告されました。

WHOが発表した2022年のデータでは、2020年には全世界で約3,770万人がヒト免疫不全ウイルス（HIV）に感染していました。

糖尿病患者の増加により、POC診断の需要も増加します。例えば、国際糖尿病連合によると、2023年には約5億3,700万人の成人（20～79歳）が糖尿病を患っています。また、同資料によると、糖尿病患者の総数は2030年までに6億4,300万人、2045年までに7億8,500万人に増加すると予測されており、予測期間中の市場成長を後押しします。

健康状態を定期的にモニターしたり、バイタルサインの異常を検出したりすることで、様々な疾患の早期診断を可能にするPOC診断の利用が拡大していることが、POC診断市場の起爆剤となると思われます。他の検査室ベースの検査は高価で、検査のために1回または数回の侵襲的なステップを必要とします。対照的に、ポイントオブケア診断薬は安価で、非侵襲的、または最小侵襲的であり、使いやすく、検査室に行く必要がないです。たとえ初期費用が高くても、ポイントオブケア診断検査は、定期的な検査よりも便利な健康状態のモニタリングのために、定期的な間隔で複数回使用することができるため、特にバイタルパラメーターやその他の臨床パラメーターの定期的なモニタリングが必要な慢性的な健康状態にある個人では、定期的な検査よりも便利です。例えば、糖尿病患者は、危険な結果を避けるために、定期的に血糖値をチェックする必要があります。

当レポートでは、世界のポイントオブケア診断市場について調査し、市場の概要とともに、製品タイプ別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 ポイントオブケア診断市場レポートのイントロダクション

第2章 ポイントオブケア診断市場のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 ポイントオブケア診断市場の主な要因分析

• ポイントオブケア診断市場の促進要因
• ポイントオブケア診断市場の抑制要因と課題
• ポイントオブケア診断市場の機会

第5章 ポイントオブケア診断市場におけるポーターのファイブフォース分析

第6章 ポイントオブケア診断市場に対するCOVID-19の影響分析

第7章 ポイントオブケア診断市場の概要

• 製品タイプ別
• 用途別
• エンドユーザー別
• 地域別

第8章 ポイントオブケア診断市場の企業と製品プロファイル

• F. Hoffmann-La Roche Ltd
• BD
• Danaher
• Abbott
• Siemens Healthcare Private Limited
• Nova Biomedical
• Quidel Corporation
• Chembio Diagnostics, Inc.
• EKF Diagnostics Holdings plc
• Trinity Biotech
• Fluxergy
• Thermo Fisher Scientific
• Quest Diagnostics Incorporated
• DiaSys Diagnostics India Pvt Ltd
• Cipla
• Sysmex Europe SE
• Lumos Diagnostics(TM)
• Trivitron Healthcare
• Getein Biotech, Inc.
• ACON Laboratories, Inc.

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis
• Table 3: Point of Care Diagnostics Market in Global (2021-2030)
• Table 4: Point of Care Diagnostics Market in Global by Product Type (2021-2030)
• Table 5: Point of Care Diagnostics Market in Global by Application (2021-2030)
• Table 6: Point of Care Diagnostics Market in Global by End-User (2021-2030)
• Table 7: Point of Care Diagnostics Market in Global by Geography (2021-2030)
• Table 8: Point of Care Diagnostics Market in North America (2021-2030)
• Table 9: Point of Care Diagnostics Market in North America by Country (2021-2030)
• Table 10: Point of Care Diagnostics Market in the US (2021-2030)
• Table 11: Point of Care Diagnostics Market in Canada (2021-2030)
• Table 12: Point of Care Diagnostics Market in Mexico (2021-2030)
• Table 13: Point of Care Diagnostics Market in Europe (2021-2030)
• Table 14: Point of Care Diagnostics Market in Europe by Country (2021-2030)
• Table 15: Point of Care Diagnostics Market in France (2021-2030)
• Table 16: Point of Care Diagnostics Market in Germany (2021-2030)
• Table 17: Point of Care Diagnostics Market in the United Kingdom (2021-2030)
• Table 18: Point of Care Diagnostics Market in Italy (2021-2030)
• Table 19: Point of Care Diagnostics Market in Spain (2021-2030)
• Table 20: Point of Care Diagnostics Market in the Rest of Europe (2021-2030)
• Table 21: Point of Care Diagnostics Market in Asia-Pacific (2021-2030)
• Table 22: Point of Care Diagnostics Market in Asia-Pacific by Country (2021-2030)
• Table 23: Point of Care Diagnostics Market in China (2021-2030)
• Table 24: Point of Care Diagnostics Market in Japan (2021-2030)
• Table 25: Point of Care Diagnostics Market in India (2021-2030)
• Table 26: Point of Care Diagnostics Market in Australia (2021-2030)
• Table 27: Point of Care Diagnostics Market in South Korea (2021-2030)
• Table 28: Point of Care Diagnostics Market in Rest of Asia-Pacific (2021-2030)
• Table 29: Point of Care Diagnostics Market in the Rest of the World (2021-2030)
• Table 30: Point of Care Diagnostics Market in RoW by Region (2021-2030)
• Table 31: Point of Care Diagnostics Market in the Middle East (2021-2030)
• Table 32: Point of Care Diagnostics Market in Africa (2021-2030)
• Table 33: Point of Care Diagnostics Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis
• Figure 3: Point of Care Diagnostics Market in Global (2021-2030)
• Figure 4: Point of Care Diagnostics Market in Global by Product Type (2021-2030)
• Figure 5: Point of Care Diagnostics Market in Global by Application (2021-2030)
• Figure 6: Point of Care Diagnostics Market in Global by End-User (2021-2030)
• Figure 7: Point of Care Diagnostics Market in Global by Geography (2021-2030)
• Figure 8: Point of Care Diagnostics Market in North America (2021-2030)
• Figure 9: Point of Care Diagnostics Market in North America by Country (2021-2030)
• Figure 10: Point of Care Diagnostics Market in the US (2021-2030)
• Figure 11: Point of Care Diagnostics Market in Canada (2021-2030)
• Figure 12: Point of Care Diagnostics Market in Mexico (2021-2030)
• Figure 13: Point of Care Diagnostics Market in Europe (2021-2030)
• Figure 14: Point of Care Diagnostics Market in Europe by Country (2021-2030)
• Figure 15: Point of Care Diagnostics Market in France (2021-2030)
• Figure 16: Point of Care Diagnostics Market in Germany (2021-2030)
• Figure 17: Point of Care Diagnostics Market in the United Kingdom (2021-2030)
• Figure 18: Point of Care Diagnostics Market in Italy (2021-2030)
• Figure 19: Point of Care Diagnostics Market in Spain (2021-2030)
• Figure 20: Point of Care Diagnostics Market in the Rest of Europe (2021-2030)
• Figure 21: Point of Care Diagnostics Market in Asia-Pacific (2021-2030)
• Figure 22: Point of Care Diagnostics Market in Asia-Pacific by Country (2021-2030)
• Figure 23: Point of Care Diagnostics Market in China (2021-2030)
• Figure 24: Point of Care Diagnostics Market in Japan (2021-2030)
• Figure 25: Point of Care Diagnostics Market in India (2021-2030)
• Figure 26: Point of Care Diagnostics Market in Australia (2021-2030)
• Figure 27: Point of Care Diagnostics Market in South Korea (2021-2030)
• Figure 28: Point of Care Diagnostics Market in Rest of Asia-Pacific (2021-2030)
• Figure 29: Point of Care Diagnostics Market in the Rest of the World (2021-2030)
• Figure 30: Point of Care Diagnostics Market in RoW by Region (2021-2030)
• Figure 31: Point of Care Diagnostics Market in the Middle East (2021-2030)
• Figure 32: Point of Care Diagnostics Market in Africa (2021-2030)
• Figure 33: Point of Care Diagnostics Market in South America (2021-2030)
• Figure 34: Market Drivers
• Figure 35: Market Barriers
• Figure 36: Marker Opportunities
• Figure 37: PORTER'S Five Force Analysis

Point of Care Diagnostics Market By Product Type (Instruments, Kits And Reagents), By Application (Blood Glucose Monitoring, Infectious Diseases, Cardio-Metabolic Diseases, Pregnancy & Fertility Testing, And Others), By End-User (Hospitals, Diagnostic Centers, Home Care Settings, And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of infectious and other lifestyle based disorders such as diabetes and cardiovascular diseases and growing awareness on health

The global point of care diagnostics market is estimated to grow at a CAGR of 6.61% during the forecast period from 2024 to 2030. The demand for point of care diagnostics is primarily being boosted by the increasing patient population suffering from various lifestyle disorders such as diabetes and cardiovascular diseases among others, the rising prevalence of infectious diseases, growing awareness regarding health and disease-free life, and innovation in product development among others, thereby contributing to the overall growth of the point of care diagnostics market during the forecast period from 2024-2030.

Point of Care Diagnostics Market Dynamics:

As per the World Health Organization (WHO) 2022 data, globally about 354 million people are still living with hepatitis. In addition, according to the Centers for Disease Control and Prevention (CDC) 2022, based upon WHO estimates, worldwide in 2019 around 296 million people had hepatitis B, 58 million people were living with hepatitis C, 1.5 million people were newly infected with chronic hepatitis B, and 1.5 million new cases of chronic hepatitis C were reported in 2019.

The data published by WHO 2022 mentioned that globally around 37.7 million people were suffering from human immunodeficiency virus (HIV) in the year 2020.

The rising number of diabetes patients will also increase the demand for point of care diagnostics. For instance, according to the International Diabetes Federation, in the year 2023, approximately 537 million adults (20-79 years) were suffering from diabetes. Also, as per the same source, the total number of people living with diabetes is projected to rise to 643 million by the year 2030 and 785 million by 2045 which will boost the market growth during the forecast period.

The growing usage of point of care diagnostics by people to regularly monitor their state of health or detect any possible abnormality in their vital signs which allows for early diagnosis of various diseases is going to act as a catalyst in point of care diagnostics market. The other lab-based tests are expensive and involve one or a few invasive steps for testing. In contrast, point-of-care diagnostics are cheaper, non-invasive, or minimally invasive and easy to use, they do not require a visit to the lab. Even if the initial cost of some point-of-care diagnostic tests is higher they can be used multiple times at regular intervals for monitoring the state of health which is more convenient than regular lab tests, especially in individuals with chronic health conditions that require regular monitoring of vital parameters and other clinical parameters. For example, patients with diabetes need to regularly check their blood glucose levels to avoid dangerous consequences.

However, errors related to the quality and accuracy of test results may restrict the growth of the point of care diagnostics market.

The point of care diagnostics market has been affected positively after the emergence of the COVID-19 infection. Although the COVID-19 pandemic impact had been unforeseen and devastating, the point of care diagnostics demand was positively influenced, as the POC diagnostic was rapidly used in the detection of COVID-19. The rapidly rising number of COVID-19 cases and the rising pressure on the government for improving patient management has further boosted the demand for rapid antigen testing kits that can be effectively used in point of care settings. Such rapidly detecting kits of point of care diagnostic are important in offering accurate disease management options. Therefore, owing to an increase in the demand for speedy diagnostic results, the adoption of point of care devices among patients is continuously on the rise.

Point of Care Diagnostics Market Segment Analysis:

Point of Care Diagnostics Market by Product Type (Instruments, Kits and Reagents), Application (Blood Glucose Monitoring, Infectious Diseases, Cardio-Metabolic Diseases, Pregnancy & Fertility Testing, and Others), End-User (Hospitals, Diagnostic Centers, Home Care Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the application segment of the point-of-care diagnostics market, the blood glucose monitoring category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the advantages and applications associated with point of care diagnostics in accurate and effective monitoring of blood glucose.

Point of Care blood glucose testing offers numerous advantages including reliable quantitative results, portable size, low cost, and simple operation among others making it a standard bedside glucose monitoring technique. For example, the cobas® pulse launched by F. Hoffmann-La Roche Ltd. in January 2022 is a smart, hand-held glucose meter for the hospital bedside. It provides reliable and precise results and helps physicians to take the best clinical decisions for all patient populations including neonates and intensive care patients

The major advantage of point of care blood glucose monitoring is rapid turn-around time which is usually less than 5 minutes and measuring glucose levels quickly and immediately, it enables healthcare professionals to take fast treatment decisions. Testing of blood glucose via point of care diagnostics requires a very small volume of blood samples and does not cause unnecessary loss of blood.

Through point of care blood glucose monitoring, patients can avoid repeated visits to hospitals, diagnostic labs, or any other medical facilities. The pre-analytical, analytical, and post-analytical errors can also be reduced with point of care blood glucose testing,

Therefore, owing to the above-mentioned factors, the blood glucose monitoring category is expected to register significant growth, thereby driving the growth of the overall point of care diagnostics market during the forecast period.

North America is expected to dominate the overall Point of Care Diagnostics Market:

Among all the regions, North America is estimated to account for the largest share of the point of care diagnostics market in the year 2023. Owing to the significance of key growth factors such as the rising prevalence of infectious diseases, increasing cases of diabetes and other lifestyle-based diseases, high disposable income, sophisticated healthcare infrastructure, presence of key players, increasing product development activities, and others, the market for point of care diagnostics is expected to witness prosperity in the region during the forecast period 2024-2030.

As per American Diabetes Association 2022, around 37.3 million people accounting for 11.3% of the US population were suffering from diabetes in 2019 and every year nearly 1.9 million people get diagnosed with diabetes in the US. Additionally, the data stated in the National Diabetes Report of the CDC, in 2020, about 88 million American adults exhibited prediabetic levels.

According to the Centers for Disease Control and Prevention (2023), it was estimated that around 1,189,700 people aged 13 and above had HIV in the US in 2019.

Coupled with the factors mentioned above, the increasing interest of product manufacturers in the region also helps in boosting regional product demand. For instance, in July 2020, BD announced the launch of the BD Veritor(TM) Plus System, a portable, rapid point of care antigen test to detect SARS-CoV-2 in almost 15 minutes. Also in November 2022, iHealth Labs received the Emergency Use Authorization for over-the-counter sale of the COVID-19 Antigen Rapid Test from the US Food and Drug Administration.

Such measures help in gaining the market share for the manufacturers as well as benefit end users in terms of better product pricing from the competition standpoint, thereby driving the North America Point of Care Diagnostics market forward during the forecast period.

Point of Care Diagnostics Market Key Players:

Some of the key market players operating in the Point of Care Diagnostics market include F. Hoffmann-La Roche Ltd., BD, Danaher, Abbott, Siemens Healthcare Private Limited, Nova Biomedical, Quidel Corporation, Chembio Diagnostics, Inc., EKF Diagnostics Holdings plc., Trinity Biotech, Fluxergy, Thermo Fisher Scientific, Quest Diagnostics Incorporated, DiaSys Diagnostics India Pvt Ltd., Cipla, Sysmex Europe SE, Lumos Diagnostics(TM), Trivitron Healthcare, Getein Biotech, Inc., ACON Laboratories, Inc., and others.

Recent Developmental Activities in the Point of Care Diagnostics Market:

In January 2023, Cipla announced the launch of a point of care testing device named Cippoint which offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and others.

In August 2022, Precision Diabetes, Inc. and DxGen Corp., entered into an exclusive agreement in the US to launch Epithod® AutoDx, a fully-automatic point of care (POC) analyzer that measures a comprehensive profile of diabetes tests.

In July 2022, QuantuMDx Group Limited, a UK-based developer of transformational point of care diagnostics, announced the launch of Q-POC(TM) - a rapid, PCR point of care diagnostic system in the UK.

Key Takeaways from the Point of Care Diagnostics Market Report Study

Market size analysis for the current point of care diagnostics market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the point of care diagnostics market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global point of care diagnostics market.

Various opportunities available for the other competitor in the point of care diagnostics market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current point of care diagnostics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for point of care diagnostics market growth in the coming future?

Target Audience who can be benefited from this Point of Care Diagnostics Market Report Study

Point of Care Diagnostics products providers

Research organizations and consulting companies

Point of Care Diagnostics-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in point of care diagnostics

Various End-users who want to know more about the point of care diagnostics market and the latest technological developments in the point of care diagnostics market.

Frequently Asked Questions for the Point of Care Diagnostics Market:

1. What is meant by point of care diagnostics?

Point of Care Diagnostics are devices that are used to perform a wide range of diagnostic tests near a patient usually in doctors' offices, hospitals, and patients' homes to gain quick feedback on the state of health of the patient.

2. What is the market for global point of care diagnostics?

The global point of care diagnostics market is estimated to grow at a CAGR of 6.61% during the forecast period from 2024 to 2030.

3. What are the drivers for the global point of care diagnostics market?

The demand for point of care diagnostics is primarily being boosted by the increasing prevalence of infectious diseases, rising technological advancements in the point of care diagnostics, the rising geriatric population associated with reduced immunity, and growing demand for point of care diagnostics for pregnancy and fertility testing among others, thereby contributing to the overall growth of the point of care diagnostics market during the forecast period from 2024-2030.

4. Who are the key players operating in the global point of care diagnostics market?

Some of the key market players operating in the point of care diagnostics market include F. Hoffmann-La Roche Ltd., BD, Danaher, Abbott, Siemens Healthcare Private Limited, Nova Biomedical, Quidel Corporation, Chembio Diagnostics, Inc., EKF Diagnostics Holdings plc., Trinity Biotech, Fluxergy, Thermo Fisher Scientific, Quest Diagnostics Incorporated, DiaSys Diagnostics India Pvt Ltd., Cipla, Sysmex Europe SE, Lumos Diagnostics(TM), Trivitron Healthcare, Getein Biotech, Inc., ACON Laboratories, Inc., and others.

5. Which region has the highest share in the point of care diagnostics market?

North America is expected to dominate the overall point of care diagnostics market during the forecast period from 2024-2030. Owing to the factors such as the rising prevalence of cardiovascular diseases, hypertension, and diabetes, the aging population, and rising government initiatives regarding disease diagnosis, the North America point of care diagnostics market is expected to witness positive growth. Furthermore, high disposable income, sophisticated healthcare infrastructure, regulatory approval for new products, and high awareness also helped the market growth in this region.

Table of Contents

1. Point of Care Diagnostics Market Report Introduction

2. Point of Care Diagnostics Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Point of Care Diagnostics Market Key Factors Analysis

• 4.1. Point of Care Diagnostics Market Drivers
  • 4.1.1. Rising prevalence of infectious and other lifestyle disorders
  • 4.1.2. Increased monitoring of the state of health by both diseased and healthy individuals
  • 4.1.3. Growing demand for point of care molecular diagnostics
• 4.2. Point of Care Diagnostics Market Restraints and Challenges
  • 4.2.1. Errors related to the quality and accuracy of test results
• 4.3. Point of Care Diagnostics Market Opportunities
  • 4.3.1. Addressing issues of limited lab services and lack of skilled professionals with the point of care diagnostics, particularly in low-income regions
  • 4.3.2. Prevention of unnecessary antibiotics prescription with the point of care diagnostics

5. Point of Care Diagnostics Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Point of Care Diagnostics Market

7. Point of Care Diagnostics Market Layout

• 7.1. By Product Type
  • 7.1.1. Instruments
  • 7.1.2. Kits and Reagents
• 7.2. By Application
  • 7.2.1. Infectious Diseases
  • 7.2.2. Blood Glucose Monitoring
  • 7.2.3. Cardiac-Metabolic Diseases
  • 7.2.4. Urological Problems
  • 7.2.5. Others
• 7.3. By End-User
  • 7.3.1. Hospitals
  • 7.3.2. Diagnostic Centers
  • 7.3.3. Homecare Settings
  • 7.3.4. Others
• 7.4. By Geography
  • 7.4.1. North America Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.1.1. United States Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.1.2. Canada Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.1.3. Mexico Point of Care Diagnostics Market Size in USD million (2021-2030)
  • 7.4.2. Europe Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.1. France Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.2. Germany Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.4. Italy Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.5. Spain Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Point of Care Diagnostics Market Size in USD million (2021-2030)
  • 7.4.3. Asia-Pacific Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.1. China Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.2. Japan Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.3. India Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.4. Australia Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.5. South Korea Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia-Pacific Point of Care Diagnostics Market Size in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW) Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.4.1. Middle East Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.4.2. Africa Point of Care Diagnostics Market Size in USD million (2021-2030)
    • 7.4.4.3. South America Point of Care Diagnostics Market Size in USD million (2021-2030)

8. Point of Care Diagnostics Market Company and Product Profiles

• 8.1. F. Hoffmann-La Roche Ltd
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. BD
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Danaher
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Abbott
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Siemens Healthcare Private Limited
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Nova Biomedical
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Quidel Corporation
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Chembio Diagnostics, Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. EKF Diagnostics Holdings plc
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Trinity Biotech
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Fluxergy
  • 8.11.1 Company Overview
  • 8.11.2 Company Snapshot
  • 8.11.3 Financial Overview
  • 8.11.4 Product Listing
  • 8.11.5 Entropy
• 8.12. Thermo Fisher Scientific
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Quest Diagnostics Incorporated
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. DiaSys Diagnostics India Pvt Ltd
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Cipla
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Sysmex Europe SE
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Lumos Diagnostics(TM)
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Trivitron Healthcare
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Getein Biotech, Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. ACON Laboratories, Inc.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us